Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Miglyol Oil 812 is a pharmaceutical-grade medium-chain triglyceride (MCT) oil, primarily composed of caprylic (C8) and capric (C10) fatty acids derived from plant sources like coconut and palm kernel oils. It is a clear, low-viscosity liquid with high oxidative stability and neutral odor and taste. It functions as a versatile excipient, drug carrier, solubilizer, emollient, and penetration enhancer in various pharmaceutical, cosmetic, and nutraceutical formulations. Its properties allow it to enhance the bioavailability and absorption of lipophilic active pharmaceutical ingredients, and it is utilized in oral, topical, and injectable drug delivery systems. It is also consumed as a dietary supplement for its metabolic benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Miglyol Oil 812.